Loading...
•
Jun 30, 2024
Curis Q2 2024 Earnings Report
Curis reported financial results for Q2 2024 and provided an operational update.
Key Takeaways
Curis reported a net loss of $11.8 million, or $2.03 per share, for the second quarter of 2024, compared to a net loss of $12.0 million, or $2.47 per share, for the same period in 2023. Revenues for the second quarter of 2024 were $2.5 million, compared to $2.2 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $28.4 million as of June 30, 2024, and expects its existing resources will enable planned operations into the first quarter of 2025.
Emavusertib was granted Orphan Drug Designation by the European Commission for the treatment of patients with primary central nervous system lymphoma.
Curis expects to have initial data for 15-20 patients with R/R PCNSL by late 2024.
Preliminary data from the TakeAim Leukemia study showed objective responses in R/R AML patients with FLT3m and SFm treated with emavusertib.
Curis expects its existing cash, cash equivalents and investments will enable its planned operations into the first quarter of 2025.
Forward Guidance
Curis expects its existing cash, cash equivalents and investments will enable its planned operations into the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...